L&C Bio Co. Ltd Net Assets
L&C Bio Co. Ltd net assets. Based on the latest financial reports, L&C Bio Co. Ltd (290650) has net assets worth ₩266.71 Billion KRW (≈ $180.74 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩497.94 Billion ≈ $337.45 Million USD) and total liabilities (₩231.24 Billion ≈ $156.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 290650 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩266.71 Billion |
| % of Total Assets | 53.56% |
| Annual Growth Rate | 60.98% |
| 5-Year Change | 391.91% |
| 10-Year Change | N/A |
| Growth Volatility | 67.08 |
Net Assets of L&C Bio Co. Ltd (2015–2024)
Net assets of L&C Bio Co. Ltd from 2015 to 2024. This chart illustrates how L&C Bio Co. Ltd's net assets have evolved over time, based on quarterly financial data. See L&C Bio Co. Ltd (290650) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for L&C Bio Co. Ltd (2015–2024)
The table below shows the annual net assets of L&C Bio Co. Ltd from 2015 to 2024. For live market cap and overall valuation, see market cap of L&C Bio Co. Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩284.35 Billion ≈ $192.70 Million |
+93.51% |
| 2023-12-31 | ₩146.94 Billion ≈ $99.58 Million |
+50.02% |
| 2022-12-31 | ₩97.95 Billion ≈ $66.38 Million |
+15.21% |
| 2021-12-31 | ₩85.02 Billion ≈ $57.62 Million |
+47.08% |
| 2020-12-31 | ₩57.81 Billion ≈ $39.17 Million |
-0.65% |
| 2019-12-31 | ₩58.18 Billion ≈ $39.43 Million |
+10.90% |
| 2018-12-31 | ₩52.46 Billion ≈ $35.55 Million |
+212.04% |
| 2017-12-31 | ₩16.81 Billion ≈ $11.39 Million |
+67.80% |
| 2016-12-31 | ₩10.02 Billion ≈ $6.79 Million |
+156.07% |
| 2015-12-31 | ₩3.91 Billion ≈ $2.65 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to L&C Bio Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8671.4% over the analyzed period, indicating profitable operations and earnings retention.
L&C Bio Co. Ltd Net Assets Breakdown (December 2024)
L&C Bio Co. Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩222.20 Billion | 78.14% |
| Common Stock | ₩11.39 Billion | 4.01% |
| Other Components | ₩50.77 Billion | 17.85% |
| Total Equity | ₩284.35 Billion | 100.00% |
L&C Bio Co. Ltd Competitors by Market Cap
The table below lists competitors of L&C Bio Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank7 Corp
NASDAQ:BSVN
|
$402.10 Million |
|
Boston Omaha Corp
NYSE:BOC
|
$402.12 Million |
|
Shanghai Lianming Machinery Co Ltd
SHG:603006
|
$402.19 Million |
|
Simei Media Co Ltd
SHE:002712
|
$402.21 Million |
|
Apex International Co Ltd
TW:4927
|
$401.91 Million |
|
Geron Co Ltd
SHE:002722
|
$401.87 Million |
|
Israel Land Development Company Co Ltd
TA:ILDC
|
$401.84 Million |
|
Shanghai Rychen Technologies Co. Ltd. A
SHE:301273
|
$401.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in L&C Bio Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 146,944,834,680 to 284,353,383,380, a change of 137,408,548,700 (93.5%).
- Net income of 141,064,260,550 contributed positively to equity growth.
- Dividend payments of 2,268,489,100 reduced retained earnings.
- Share repurchases of 1,290,000,460 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩141.06 Billion | +49.61% |
| Dividends Paid | ₩2.27 Billion | -0.8% |
| Share Repurchases | ₩1.29 Billion | -0.45% |
| Other Changes | ₩-97.22 Million | -0.03% |
| Total Change | ₩- | 93.51% |
Book Value vs Market Value Analysis
This analysis compares L&C Bio Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.92x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 38.03x to 1.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩633.63 | ₩24100.00 | x |
| 2017-12-31 | ₩938.58 | ₩24100.00 | x |
| 2018-12-31 | ₩2417.28 | ₩24100.00 | x |
| 2019-12-31 | ₩2635.33 | ₩24100.00 | x |
| 2020-12-31 | ₩2640.02 | ₩24100.00 | x |
| 2021-12-31 | ₩3747.89 | ₩24100.00 | x |
| 2022-12-31 | ₩4317.94 | ₩24100.00 | x |
| 2023-12-31 | ₩6477.65 | ₩24100.00 | x |
| 2024-12-31 | ₩12534.92 | ₩24100.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently L&C Bio Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 49.61%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 195.67%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.67x
- Recent ROE (49.61%) is above the historical average (21.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 30.72% | 13.36% | 0.99x | 2.33x | ₩810.77 Million |
| 2016 | 19.77% | 16.76% | 0.75x | 1.56x | ₩979.17 Million |
| 2017 | 22.32% | 20.97% | 0.87x | 1.22x | ₩2.07 Billion |
| 2018 | 9.93% | 24.52% | 0.37x | 1.09x | ₩-38.59 Million |
| 2019 | 12.46% | 24.87% | 0.44x | 1.14x | ₩1.43 Billion |
| 2020 | 18.71% | 32.79% | 0.41x | 1.39x | ₩5.03 Billion |
| 2021 | 16.25% | 30.24% | 0.43x | 1.26x | ₩5.31 Billion |
| 2022 | 4.64% | 8.64% | 0.26x | 2.04x | ₩-5.25 Billion |
| 2023 | 32.91% | 73.36% | 0.25x | 1.78x | ₩33.67 Billion |
| 2024 | 49.61% | 195.67% | 0.15x | 1.67x | ₩112.63 Billion |
Industry Comparison
This section compares L&C Bio Co. Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $135,842,768,788
- Average return on equity (ROE) among peers: 9.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| L&C Bio Co. Ltd (290650) | ₩266.71 Billion | 30.72% | 0.87x | $402.08 Million |
| Shinhung (004080) | $106.86 Billion | 7.92% | 0.32x | $91.86 Million |
| HansBiomed Corporation (042520) | $39.39 Billion | 8.88% | 0.13x | $136.42 Million |
| JVM Co. Ltd (054950) | $112.17 Billion | 9.89% | 0.57x | $188.89 Million |
| U&I Corporation (056090) | $28.54 Billion | -17.41% | 1.63x | $313.85 Million |
| Huvitz Co. Ltd (065510) | $78.48 Billion | -3.47% | 0.98x | $46.00 Million |
| Vieworks Co. Ltd (100120) | $126.17 Billion | 15.56% | 0.09x | $176.92 Million |
| Corentec Co Ltd (104540) | $56.27 Billion | -1.53% | 0.27x | $42.50 Million |
| SD Biosensor Inc (137310) | $757.55 Billion | 81.27% | 0.93x | $518.00 Million |
| Hironic Co. Ltd (149980) | $37.75 Billion | -0.69% | 0.14x | $39.75 Million |
| Humasis Co. Ltd (205470) | $15.24 Billion | -8.04% | 1.39x | $172.92 Million |
About L&C Bio Co. Ltd
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.